1. Home
  2. DV vs COAG Comparison

DV vs COAG Comparison

Compare DV & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DoubleVerify Holdings Inc.

DV

DoubleVerify Holdings Inc.

HOLD

Current Price

$11.45

Market Cap

1.6B

Sector

Technology

ML Signal

HOLD

Logo Hemab Therapeutics Holdings Inc. Common Stock

COAG

Hemab Therapeutics Holdings Inc. Common Stock

N/A

Current Price

$48.77

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DV
COAG
Founded
2008
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.4B
IPO Year
2021
2026

Fundamental Metrics

Financial Performance
Metric
DV
COAG
Price
$11.45
$48.77
Analyst Decision
Buy
Analyst Count
15
0
Target Price
$16.37
N/A
AVG Volume (30 Days)
3.2M
245.1K
Earning Date
05-06-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.04
N/A
Revenue
$748,291,000.00
N/A
Revenue This Year
$12.68
N/A
Revenue Next Year
$9.75
N/A
P/E Ratio
$295.88
N/A
Revenue Growth
13.92
N/A
52 Week Low
$7.61
$27.47
52 Week High
$16.82
$45.27

Technical Indicators

Market Signals
Indicator
DV
COAG
Relative Strength Index (RSI) 55.38 73.98
Support Level $10.76 $28.51
Resistance Level $11.58 N/A
Average True Range (ATR) 0.42 4.26
MACD 0.01 1.57
Stochastic Oscillator 55.29 93.46

Price Performance

Historical Comparison
DV
COAG

About DV DoubleVerify Holdings Inc.

DoubleVerify Holdings Inc is a media effectiveness platform that leverages artificial intelligence (AI) to drive superior outcomes for international brands by creating transparent ad transactions. Its solutions provide unbiased data analytics to improve the effectiveness, quality and return on advertising investments. DV Authentic Ad is its proprietary metric measuring whether an ad was delivered in a brand suitable environment, fully viewable, by a real person and in geography, while DV Pinnacle delivers these metrics in real time. The Company's solutions are integrated across programmatic platforms, social media channels and digital publishers, and are accredited by the Media Rating Council for digital ad measurement. It operates in the United States and international markets.

About COAG Hemab Therapeutics Holdings Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Share on Social Networks: